Variation in Health-Related Quality of Life by Age Among Patients with Chronic Lymphocytic Leukemia

Abstract

Abstract 2085 Introduction.Although advanced patient age is commonly used as a factor in selecting therapy for patients with chronic lymphocytic leukemia (CLL), based on presumed associations with functional status, limited data exist regarding the relationships between age and physical, emotional, social, and functional well being. We examined the relationships between age and these domains of health-related quality of life (HRQOL) for CLL patients treated in US community practices. Methods.Baseline data were collected as part of Connect CLL®, a prospective observational registry initiated in March 2010 involving centers in the US. Data on patient demographics and clinical characteristics were provided by clinicians. HRQOL was self-reported by patients in the clinic at enrollment. Patients completed 3 psychometrically validated instruments: the Brief Fatigue Inventory (BFI), EQ-5D, and Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu). Standard analyses were conducted of each instrument given clinical characteristics at that time. Reported mean BFI, EQ-5D and FACT-Leu scores were analyzed by age group (<65, 65–74, >74). Statistical significance of score differences among sub-cohorts was ascertained by ANOVA using SAS 9.1. Results.Baseline HRQOL data were reported by 604 patients, enrolled from 161 centers. Patients were predominantly male (62%) and white (90%) with mean age at 69.9 (standard deviation [SD] 11.2) yrs. HRQOL scores by age group are presented:Baseline HRQOL by Age GroupHRQOL ScoresAge <65 (n=197)Age 65–74 (n=185)Age >= 75 (n=222)P-valueBFI Mean(SD)Global4.4 (2.5)4.1 (2.3)4.5 (2.5)0.2738Severity4.9 (2.6)4.9 (2.6)5.3 (2.8)0.1536Interference4.1 (2.6)3.7 (2.4)4.1 (2.6)0.2795EQ-5DVAS Scale Mean(SD)71.4 (19.7)71.4 (22.5)68.6 (21.2)0.3501Mobility Mean(SD)1.2 (0.4)1.2 (0.4)1.4 (0.5)<.0001Self Care Mean(SD)1.1 (0.2)1.0 (0.2)1.1 (0.3)0.0724Usual Activities Mean(SD)1.4 (0.5)1.3 (0.5)1.5 (0.6)0.0164Pain/Discomfort Mean(SD)1.4 (0.6)1.3 (0.5)1.6 (0.5)0.0002Anxiety/Depression Mean(SD)1.3 (0.5)1.3 (0.5)1.3 (0.5)0.7725FACT-LEU Mean(SD)Physical21.7 (5.2)23.0 (4.2)22.4 (4.5)0.0365Social/Family23.2 (5.1)23.7 (5.1)23.3 (5.8)0.7227Emotional18.6 (3.8)19.3 (3.4)19.3 (3.7)0.1059Functional19.5 (5.7)20.4 (6.0)19.5 (6.3)0.2185CLL subscale Score48.5 (10.6)50.0 (9.6)47.4 (10.6)0.0634FACT-G Total83.0 (15.1)86.5 (13.6)84.5 (14.6)0.0830FACT-LEU Total131.5 (23.5)136.5 (20.7)132.1 (22.7)0.0846There were no significant differences between the age groups in fatigue as measured by the BFI, or differences in overall HRQOL as measured by the EQ-5D Visual Analogue Scale (VAS) or the FACT-G. Anxiety/depression and self care are EQ-5D domains that also did not vary by age. Although mobility was most impaired in the oldest age group compared to the two younger groups, usual activities and pain/discomfort were worse in both the younger and older cohorts compared to those 65–74 years of age. FACT-Leu results indicated that the social/family domain scores did not vary by age, but that physical, emotional, and functional domains did vary statistically with the oldest typically doing better than the 65–74 year olds, but not necessarily better than those <65. Conclusions.Initial results from the Connect CLL® Registry indicate that HRQOL does not worsen monotonically with older age. In this cohort, both the youngest and oldest age groups had worse HRQOL in certain domains, presenting an inverted v-shaped relationship. Future analyses should be conducted on: (1) how HRQOL may be affected over time with changes in disease; and, (2) how HRQOL may be influenced by alternative therapies. Results reported here should serve as a useful baseline reference. Disclosures:Pashos:Celgene: Membership on an entity's Board of Directors or advisory committees. Flowers:Genentech/Roche (unpaid): Consultancy; Celgene: Consultancy; Millennium/Takeda: Research Funding; Wyeth: Research Funding; Novartis: Research Funding. Weiss:Celgene: Membership on an entity's Board of Directors or advisory committees. Lamanna:Celgene: Membership on an entity's Board of Directors or advisory committees. Farber:Celgene: Membership on an entity's Board of Directors or advisory committees. Kipps:Igenica: Equity Ownership, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Research Funding; Abbot Industries: Research Funding; Pharmacyclics: Membership on an entity's Board of Directors or advisory committees; Genentech: Research Funding; GSK: Research Funding; Gilead Sciences: Consultancy, Research Funding; Amgen: Research Funding. Lerner:Celgene: Membership on an entity's Board of Directors or advisory committees. Kay:Celgene: Membership on an entity's Board of Directors or advisory committees. Sharman:Celgene: Membership on an entity's Board of Directors or advisory committees. Grinblatt:Celgene: Membership on an entity's Board of Directors or advisory committees. Flinn:Celgene: Membership on an entity's Board of Directors or advisory committees. Kozloff:Celgene: Membership on an entity's Board of Directors or advisory committees. Swern:Celgene Corporation: Employment, Equity Ownership. Kahn:Celgene Corporation: Employment, Equity Ownership. Street:Celgene: Employment, Equity Ownership. Sullivan:Celgene: Employment, Equity Ownership. Keating:Celgene: Membership on an entity's Board of Directors or advisory committees.